The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries.

At least 870 subjects, with leg pain caused by a narrowing of their leg arteries will take part in this study.

Both Niaspan and lovastatin (Mevacor®) are approved by the United States Food and Drug Administration (FDA) to treat high cholesterol. Niacin ER/Lovastatin (Advicor®), a combination of these two drugs, is also approved by the FDA to treat high cholesterol. The use of Niacin ER/Lovastatin to treat narrowing of leg arteries and relieve “intermittent claudication” (leg pain caused by narrowing of the arteries in the leg) is considered investigational. An investigational use is one that is not approved by the FDA.

Clinical Trial Description

This is a Phase 3, 32-week, double-blind, diet-intervention, randomized, parallel group, ten-arm, multi-center, multi-national, dose titration study evaluating the safety and efficacy of NL in patients with intermittent claudication (IC).

The objectives of this study are to evaluate the safety and efficacy of NL in patients with IC. The primary efficacy analysis will be the percent change from baseline in Peak Walking Time (PWT) calculated from the natural logarithm of the ratio of the time walked on treadmill at the Week 32 Visit divided by the time walked at baseline. Other efficacy measures will include Claudication Onset Time (COT) percent changes from baseline to Week 32 , changes in Ankle Brachial Index (ABI), Quality of Life (QoL) percent changes at Weeks 20 and 32, lower limb amputations, composite of cardiovascular events (MI, stroke, and vascular death), and coronary and peripheral artery revascularizations. Safety variables will include serum transaminases, routine chemistry parameters, hematology, and adverse events. Pharmacokinetic analyses will be conducted as well. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00071266
Study type	Interventional
Source	Kos Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	October 2003

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05335525` - Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
Active, not recruiting	`NCT01903044` - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating	Phase 1/Phase 2
Completed	`NCT02228564` - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease	N/A
Completed	`NCT02271529` - Zilver PTX Delivery System	N/A
Recruiting	`NCT02054871` - RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty	N/A
Completed	`NCT00822172` - Evaluation of Cilostazol in Combination With L-Carnitine	Phase 4
Completed	`NCT00574782` - Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)	N/A
Completed	`NCT00029991` - Extract of Ginkgo Biloba (EGB 761) and Vascular Function	Phase 1/Phase 2
Completed	`NCT01355406` - Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System	N/A
Recruiting	`NCT05804097` - Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?	Phase 4
Recruiting	`NCT03638115` - The VaSecure BTK Study	N/A
Active, not recruiting	`NCT03241459` - Safety and Efficacy of the SurVeil™ Drug-Coated Balloon	N/A
Active, not recruiting	`NCT01661231` - Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe	N/A
Completed	`NCT01722877` - JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions	N/A
Completed	`NCT01444378` - Absolute Pro® MOMENTUM™	N/A
Completed	`NCT00753337` - The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study	N/A
Completed	`NCT00538226` - Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg	Phase 1
Completed	`NCT00593385` - Atrium iCAST Iliac Stent Pivotal Study	N/A
Recruiting	`NCT00385385` - RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease	Phase 2
Completed	`NCT00392509` - ALD-301 for Critical Limb Ischemia, Randomized Trial	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms